Anna Vikman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Vikman has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anita Ignatius
Institute of Orthopedic Research and Biomechanics, Ulm University Medical Center, Germany
1 shared publication - Anne Dudeck
Institute for Clinical Immunology and Cell Therapeutics, Medical Faculty, Otto-von-Guericke University Magdeburg, Germany
1 shared publication - Benjamin Thilo Krüger
Institute of Orthopedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany
1 shared publication - Deniz Ragipoglu
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, 68167 Mannheim, Germany
1 shared publication - Jasmin Bülow
Institute of Orthopedic Research and Biomechanics, University Medical Center Ulm, 89081 Ulm, Germany
1 shared publication - Konstantinos Katsoulis-Dimitriou
Institute for Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany
1 shared publication
Latest Publications
- Open Access
- 23 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9135
Role of Mast-Cell-Derived RANKL in Ovariectomy-Induced Bone Loss in Mice
Mast cells may contribute to osteoporosis development, because patients with age-related or post-menopausal osteoporosis exhibit more mast cells in the bone marrow, and mastocytosis patients frequently suffer from osteopenia. We previously showed that mast cells crucially regulated osteoclastogenesis and bone loss in ovariectomized, estrogen-depleted mice in a preclinical model for post-menopausal osteoporosis and found that granular mast cell mediators were responsible for these estrogen-dependent effects. However, the role of the key regulator of osteoclastogenesis, namely, receptor activator of NFκB ligand (RANKL), which is secreted by mast cells, in osteoporosis development has, to date, not been defined. Here, we investigated whether mast-cell-derived RANKL participates in ovariectomy (OVX)-induced bone loss by using female mice with a conditional Rankl deletion. We found that this deletion in mast cells did not influence physiological bone turnover and failed to protect against OVX-induced bone resorption in vivo, although we demonstrated that RANKL secretion was significantly reduced in estrogen-treated mast cell cultures. Furthermore, Rankl deletion in mast cells did not influence the immune phenotype in non-ovariectomized or ovariectomized mice. Therefore, other osteoclastogenic factors released by mast cells might be responsible for the onset of OVX-induced bone loss.
- 23 May 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9135
Open AccessRole of Mast-Cell-Derived RANKL in Ovariectomy-Induced Bone Loss in Mice
Mast cells may contribute to osteoporosis development, because patients with age-related or post-menopausal osteoporosis exhibit more mast cells in the bone marrow, and mastocytosis patients frequently suffer from osteopenia. We previously showed that mast cells crucially regulated osteoclastogenesis and bone loss in ovariectomized, estrogen-depleted mice in a preclinical model for post-menopausal osteoporosis and found that granular mast cell mediators were responsible for these estrogen-dependent effects. However, the role of the key regulator of osteoclastogenesis, namely, receptor activator of NFκB ligand (RANKL), which is secreted by mast cells, in osteoporosis development has, to date, not been defined. Here, we investigated whether mast-cell-derived RANKL participates in ovariectomy (OVX)-induced bone loss by using female mice with a conditional Rankl deletion. We found that this deletion in mast cells did not influence physiological bone turnover and failed to protect against OVX-induced bone resorption in vivo, although we demonstrated that RANKL secretion was significantly reduced in estrogen-treated mast cell cultures. Furthermore, Rankl deletion in mast cells did not influence the immune phenotype in non-ovariectomized or ovariectomized mice. Therefore, other osteoclastogenic factors released by mast cells might be responsible for the onset of OVX-induced bone loss.